NASDAQ:MESOMesoblast Stock Price, Forecast & News

Mesoblast's stock was trading at $6.0250 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MESO shares have increased by 112.9% and is now trading at $12.83. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mesoblast.

Mesoblast is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020. View our earnings forecast for Mesoblast.

Mesoblast limited (NASDAQ:MESO) posted its quarterly earnings data on Wednesday, May, 27th. The company reported ($0.14) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.14). The business had revenue of $12.20 million for the quarter, compared to analyst estimates of $9.38 million. Mesoblast had a negative net margin of 197.65% and a negative return on equity of 13.59%. View Mesoblast's earnings history.

7 analysts have issued 12 month price targets for Mesoblast's stock. Their forecasts range from $6.00 to $23.00. On average, they anticipate Mesoblast's stock price to reach $15.04 in the next twelve months. This suggests a possible upside of 17.2% from the stock's current price. View analysts' price targets for Mesoblast.

News headlines about MESO stock have trended neutral recently, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Mesoblast earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutMesoblast.

Some companies that are related to Mesoblast include Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Ablynx (ABLYF), bluebird bio (BLUE), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC) and Fate Therapeutics (FATE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Exelixis (EXEL), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), TherapeuticsMD (TXMD), AbbVie (ABBV), Sangamo Therapeutics (SGMO) and Aduro BioTech (ADRO).

(MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Mesoblast's stock is owned by a number of institutional and retail investors. Top institutional shareholders include M&G Investment Management Ltd. (1.32%), Penbrook Management LLC (0.21%), Morgan Stanley (0.07%), Wilbanks Smith & Thomas Asset Management LLC (0.05%), Aperio Group LLC (0.02%) and Jane Street Group LLC (0.01%).

MESO stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Jane Street Group LLC, and Penbrook Management LLC.

MESO stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Wilbanks Smith & Thomas Asset Management LLC, Aperio Group LLC, Ingalls & Snyder LLC, and Cetera Advisor Networks LLC.

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MESO stock can currently be purchased for approximately $12.83.

Mesoblast has a market capitalization of $1.49 billion and generates $16.72 million in revenue each year. The company earns $-89,800,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Mesoblast employs 81 workers across the globe.

The official website for Mesoblast is www.mesoblast.com.

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]